Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features-Reference-Cited by-同舟云学术

Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features

Published:2015-11 Issue:5 Volume:68 Page:912-914
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Geynisman Daniel M.

Publisher

Elsevier BV

Subject

Urology

Reference6 articles.

1. Immune checkpoint blockade in cancer therapy;Postow;J Clin Oncol,2015

2. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial;Motzer;J Clin Oncol,2015

3. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials;Godwin;Discov Med,2014

4. Molecular genetics of clear-cell renal cell carcinoma;Brugarolas;J Clin Oncol,2014

5. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma;Ho;Urol Oncol,2015

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non‐clear‐cell renal cell carcinoma;BJU International;2023-11-20

2. Clinicopathologic and Immunohistochemical Characterization of Sarcomatoid Chromophobe Renal Cell Carcinoma;American Journal of Surgical Pathology;2022-06-13

3. Complete Response of Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)-Associated Renal Cell Carcinoma to Pembrolizumab Immunotherapy: A Case Report;Frontiers in Oncology;2021-10-15

4. Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview;Expert Review of Anticancer Therapy;2021-08-06

5. Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study;Targeted Oncology;2021-08-02